Acadian Asset Management
VIRX

Acadian Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Acadian Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,908
Closed -$2K – 2266
2024
Q3 		$2K Hold
10,908
– – ﹤0.01% 2044
2024
Q2 		$5K Hold
10,908
– – ﹤0.01% 1717
2024
Q1 		$11K Sell
10,908
-53,782
-83% -$39.3K ﹤0.01% 1511
2023
Q4 		$36K Sell
64,690
-32,419
-33% -$19.9K ﹤0.01% 1504
2023
Q3 		$99K Sell
97,109
-70,709
-42% -$96K ﹤0.01% 1307
2023
Q2 		$235K Buy
167,818
+71,683
+75% +$103K ﹤0.01% 1239
2023
Q1 		$151K Hold
96,135
– – ﹤0.01% 1313
2022
Q4 		$139K Buy
+96,135
New +$281K ﹤0.01% 1367

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's VIRX Position: Q4 2024 in Review

Acadian Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2024, closing a stake of 10,908 shares — an estimated $2K sold.

Acadian Asset Management first reported a position in VIRX in Q4 2022 and held it in 8 quarters. The position peaked at $235K in Q2 2023. 32 funds tracked by Wall St. Rank hold VIRX as of Q4 2024.

  • Acadian Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 10,908 Viracta Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $2K.
  • Acadian Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2022 and held it in 8 quarters.
  • Acadian Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $235K in Q2 2023.
  • 32 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.